Alsner J - Search Results

1

Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer.

Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Deng L, Broaddus R, Lluch A, Aparicio S, Brown P, Pusztai L, Symmans WF, Alsner J, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coombes KR, Mills GB. Gonzalez-Angulo AM, et al. Among authors: alsner j. Clin Proteomics. 2011 Jul 8;8(1):11. doi: 10.1186/1559-0275-8-11. Clin Proteomics. 2011. PMID: 21906370 Free PMC article.

2

Radiation dose to heart and cardiac substructures and risk of coronary artery disease in early breast cancer patients: A DBCG study based on modern radiation therapy techniques.

Holm Milo ML, Slot Møller D, Bisballe Nyeng T, Hoffmann L, Dahl Nissen H, Jensen I, Laugaard Lorenzen E, Bech Jellesmark Thorsen L, Melgaard Nielsen K, Paaske Johnsen S, Brink Valentin J, Alsner J, Vrou Offersen B. Holm Milo ML, et al. Among authors: alsner j. Radiother Oncol. 2023 Mar;180:109453. doi: 10.1016/j.radonc.2022.109453. Epub 2023 Jan 13. Radiother Oncol. 2023. PMID: 36642388

3

The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma.

Horsman MR, Alsner J, Overgaard J. Horsman MR, et al. Among authors: alsner j. Acta Oncol. 1998;37(5):441-5. doi: 10.1080/028418698430386. Acta Oncol. 1998. PMID: 9831372

4

TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer.

Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner J. Overgaard J, et al. Among authors: alsner j. Acta Oncol. 2000;39(3):327-33. doi: 10.1080/028418600750013096. Acta Oncol. 2000. PMID: 10987229

5

Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients.

Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J. Alsner J, et al. Clin Cancer Res. 2000 Oct;6(10):3923-31. doi: 10.1186/bcr109. Clin Cancer Res. 2000. PMID: 11051239 Free PMC article.

6

Interaction between potential doubling time and TP53 mutation: predicting radiotherapy outcome in squamous cell carcinoma of the head and neck.

Alsner J, Høyer M, Sørensen SB, Overgaard J. Alsner J, et al. Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):519-25. doi: 10.1016/s0360-3016(00)01489-9. Int J Radiat Oncol Biol Phys. 2001. PMID: 11173149

7

TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck.

Alsner J, Sørensen SB, Overgaard J. Alsner J, et al. Radiother Oncol. 2001 May;59(2):179-85. doi: 10.1016/s0167-8140(01)00301-2. Radiother Oncol. 2001. PMID: 11325447

8

Does variability in normal tissue reactions after radiotherapy have a genetic basis--where and how to look for it?

Andreassen CN, Alsner J, Overgaard J. Andreassen CN, et al. Among authors: alsner j. Radiother Oncol. 2002 Aug;64(2):131-40. doi: 10.1016/s0167-8140(02)00154-8. Radiother Oncol. 2002. PMID: 12242122 Review.

9

Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes.

Andreassen CN, Alsner J, Overgaard M, Overgaard J. Andreassen CN, et al. Among authors: alsner j. Radiother Oncol. 2003 Nov;69(2):127-35. doi: 10.1016/j.radonc.2003.09.010. Radiother Oncol. 2003. PMID: 14643949

10

Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas.

Eriksen JG, Buffa FM, Alsner J, Steiniche T, Bentzen SM, Overgaard J. Eriksen JG, et al. Among authors: alsner j. Radiother Oncol. 2004 Sep;72(3):275-82. doi: 10.1016/j.radonc.2004.07.014. Radiother Oncol. 2004. PMID: 15450725 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

155 results

Search Page